Galenica Ab

Galenica Ab company information, Employees & Contact Information

Explore related pages

Related company profiles:

Galenica is a Swedish privately owned pharmaceutical company, authorized and audited by the Swedish Medical Product Agency. Galenica was founded in 1999 and has grown to 70 employees with expertise and balance between academic knowledge and industrial experience. Galenica is located in Medeon Science Park with 4000 m² state-of-the-art facilities. Our activities are divided into two business units: Contract Development Manufacturing Organization (CDMO) and Development and launching of own branded pharmaceutical products (Derma). Within CDMO (Contract Development Manufacturing Organization), Galenica supports and guides our partners in their pharmaceutical development programs and manufactures commercially niched products for our customers to bring to the market. We have vast expertise in pharmaceutical and analytical development as well as in production of Clinical Trial Material (CTM) for Phase I up to Phase III of all common non-sterile dosage forms. The Derma unit actively develops and launches our own pharmaceutical products which has a focus on derma, utilizing our state-of-the-art expertise in drug formulation, manufacturing, and quality control. Galenica has a proven track record when it comes to quality, knowledge and flexibility as well as keeping timelines. We combine state-of-the-art equipment with strong personal commitment, far-reaching clinical experience with tough perseverance, expertise in drug formulation with a solution-oriented determination. Since the start, we have supported and guided hundreds of clients in their pharmaceutical development programs and launched several self-made products.

Company Details

Employees
68
Founded
-
Address
Medeon Science Park, Malmö,skåne 20512,sweden
Phone
(464)032-1095
Email
in****@****nica.se
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Malmö, Skåne
Looking for a particular Galenica Ab employee's phone or email?

Galenica Ab Questions

News

Galenica AG Reports Robust Q3 Growth and Raises Guidance - TipRanks

Galenica AG Reports Robust Q3 Growth and Raises Guidance TipRanks

Baker McKenzie Advises UBS on the Financing of Galenica’s Acquisition of the Labor Team Group - Baker McKenzie

Baker McKenzie Advises UBS on the Financing of Galenica’s Acquisition of the Labor Team Group Baker McKenzie

While institutions own 45% of Galenica AG (VTX:GALE), retail investors are its largest shareholders with 55% ownership - simplywall.st

While institutions own 45% of Galenica AG (VTX:GALE), retail investors are its largest shareholders with 55% ownership simplywall.st

Switzerland: Galenica enters diagnostics market with acquisition of Labor Team Group - Investors in Healthcare

Switzerland: Galenica enters diagnostics market with acquisition of Labor Team Group Investors in Healthcare

Galenica AG News Today: Stock Surges Amid Acquisition Speculation - Meyka

Galenica AG News Today: Stock Surges Amid Acquisition Speculation Meyka

Here's Why Galenica AG's (VTX:GALE) CEO May Have Their Pay Bumped Up - simplywall.st

Here's Why Galenica AG's (VTX:GALE) CEO May Have Their Pay Bumped Up simplywall.st

Pharmaceuticals: Galenica sets itself higher profit target after half-year | blue News - blue News

Pharmaceuticals: Galenica sets itself higher profit target after half-year | blue News blue News

3 Q&A interview with Kristina Thored, Vice President CDMO, MVA member Galenica - mva.org

3 Q&A interview with Kristina Thored, Vice President CDMO, MVA member Galenica mva.org

Despite Its High P/E Ratio, Is Galenica AG (VTX:GALE) Still Undervalued? - Yahoo Finance

Despite Its High P/E Ratio, Is Galenica AG (VTX:GALE) Still Undervalued? Yahoo Finance

Galenica Group focuses on pharmaceuticals as it becomes Vifor Pharma Group - News-Medical

Galenica Group focuses on pharmaceuticals as it becomes Vifor Pharma Group News-Medical

Galenica Sante raises $1.9 billion in Europe's biggest IPO this year - Reuters

Galenica Sante raises $1.9 billion in Europe's biggest IPO this year Reuters

All change at Galenica with split, IPO and name change - The Pharma Letter

All change at Galenica with split, IPO and name change The Pharma Letter

Galenica strengthens basic care with new pharmacy concept - sharewise.com

Galenica strengthens basic care with new pharmacy concept sharewise.com

Galenica Group to Acquire Relypsa for $1.53B - Genetic Engineering and Biotechnology News

Galenica Group to Acquire Relypsa for $1.53B Genetic Engineering and Biotechnology News

Vifor Pharma to top cardio-renal care after Galenica completes Relyapsa acquisition - European Pharmaceutical Review

Vifor Pharma to top cardio-renal care after Galenica completes Relyapsa acquisition European Pharmaceutical Review

Planzer and Galenica launch Health Supply AG - Switzerland Global Enterprise

Planzer and Galenica launch Health Supply AG Switzerland Global Enterprise

Galenica snaps up Relypsa and its Veltassa med for $1.53B in march toward Vifor spinoff - Fierce Pharma

Galenica snaps up Relypsa and its Veltassa med for $1.53B in march toward Vifor spinoff Fierce Pharma

Relypsa Inc: RLYP Stock Pops 60% on Galenica Buyout Bid - Nasdaq

Relypsa Inc: RLYP Stock Pops 60% on Galenica Buyout Bid Nasdaq

Galenica AG Unveils Innovative Pharmacy Concept to Enhance Healthcare Services - TipRanks

Galenica AG Unveils Innovative Pharmacy Concept to Enhance Healthcare Services TipRanks

The Returns At Galenica (VTX:GALE) Aren't Growing - simplywall.st

The Returns At Galenica (VTX:GALE) Aren't Growing simplywall.st

Galenica To Acquire Relypsa For $32 A Share - Yahoo Finance

Galenica To Acquire Relypsa For $32 A Share Yahoo Finance

Relypsa finally finds a buyer as Veltassa partner Galenica coughs up $1.5B - Fierce Biotech

Relypsa finally finds a buyer as Veltassa partner Galenica coughs up $1.5B Fierce Biotech

Galenica and Relypsa Announce Agreement for Galenica to Acquire Relypsa - GlobeNewswire

Galenica and Relypsa Announce Agreement for Galenica to Acquire Relypsa GlobeNewswire

Galenica (VTX:GALE) shareholders have earned a 9.4% CAGR over the last five years - simplywall.st

Galenica (VTX:GALE) shareholders have earned a 9.4% CAGR over the last five years simplywall.st

Galenica Group strengthens management team - PMLiVE

Galenica Group strengthens management team PMLiVE

Galenica confident of meeting annual targets after strong half-year - SWI swissinfo.ch

Galenica confident of meeting annual targets after strong half-year SWI swissinfo.ch

First Galenica block ends three times covered - GlobalCapital

First Galenica block ends three times covered GlobalCapital

EU clears Fresenius, Galenica pharma joint venture - Reuters

EU clears Fresenius, Galenica pharma joint venture Reuters

Apotheken-Netzwerk Galenica fühlt mit Zeam GenZ-Puls - markt-kom.com

Apotheken-Netzwerk Galenica fühlt mit Zeam GenZ-Puls markt-kom.com

Swiss Firm Galenica Group Buys Aspreva Pharmaceuticals For US$26.00 Per Share In Cash - Update - RTTNews

Swiss Firm Galenica Group Buys Aspreva Pharmaceuticals For US$26.00 Per Share In Cash - Update RTTNews

Bankruptcy in "Galenica" due to a tax debt of 2,6 million - vijesti.me

Bankruptcy in "Galenica" due to a tax debt of 2,6 million vijesti.me

The medicines arrive by the end of August, the debt to Galenica remains - vijesti.me

The medicines arrive by the end of August, the debt to Galenica remains vijesti.me

Top Galenica Ab Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant